Contraband ContraBand: the only heart failure medical device that is placed outside the heart
- Coordinator
- Restore Medical Ltd, Israel
- Runs
- 1 December 2022 to 30 November 2024
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190178748
What the project is doing
In the project's own words, from its summary on CORDIS.
Worldwide 26 million people suffer from Congestive Heart Failure (CHF), a chronic condition that worsens with time and leads to staggering healthcare costs and a significant reduction of quality of life. ContraBand is an implantable device aiming to restore heart function in patient suffering from left ventricle failure. ContraBand’s benefits include built-in fail-safe for full reversibility of functionality, tremendous ease of use due to its proprietary stеnt-within-a-stеnt design and transcatheter delivery system, and full clinical flexibility to be compatible with pharmacotherapies and other CHF devices.
In the project, we will finalise clinical development and introduce ContraBand into clinical routines in Europe. We expect to launch ContraBand in 2024, generate €15M in revenues in 2025 and €60M in 2026. Before market launch, we will create >95 jobs at the company in strategic locations in Europe.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Restore Medical Ltd | Or Yehuda | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI